Typhoid Vaccine Age Recommendations
Children can receive typhoid vaccine starting at 6 months of age with the parenteral (injectable) inactivated vaccine, though current evidence strongly supports vaccination beginning at 9 months of age with newer conjugate vaccines for optimal immunogenicity and safety.
Age-Specific Vaccination Guidelines
Parenteral Inactivated Vaccine
Based on ACIP guidelines, the traditional parenteral inactivated typhoid vaccine can be administered to:
- Children 6 months to <10 years: 0.25 ml subcutaneously, given as two doses separated by ≥4 weeks 1
- Children ≥10 years and adults: 0.5 ml subcutaneously, given as two doses separated by ≥4 weeks 1
Oral Live-Attenuated Ty21a Vaccine
- Children <10 years: Four enteric-coated capsules taken on alternate days 1
- Children ≥10 years and adults: Same four-capsule regimen 1
Important caveat: The guidelines note limited experience with oral Ty21a vaccine in children <5 years of age 1, making this less ideal for younger children.
Modern Conjugate Vaccine Evidence
Recent high-quality research demonstrates that typhoid conjugate vaccines (TCV) are highly effective and safe starting at 9 months of age:
A 2021 cluster-randomized trial in Bangladesh showed Vi-TT conjugate vaccine provided 85% protection in children vaccinated from 9 months to <16 years, with consistent protection even in children under 2 years (81% efficacy) 2
A 2020 phase II trial confirmed Vi-DT conjugate vaccine achieved 100% seroconversion in children aged 6-23 months with excellent safety 3
A 2022 study demonstrated that Typbar-TCV® can be safely co-administered with measles or MMR vaccines at 9 months of age 4
Practical Dosing Algorithm
For children in endemic areas or travelers:
Age 6-8 months: Use parenteral inactivated vaccine (0.25 ml × 2 doses) if urgent protection needed, though immune response may be suboptimal 5
Age 9-12 months (PREFERRED): Administer typhoid conjugate vaccine (Vi-TT or Typbar-TCV®) as single 0.5 ml intramuscular dose, ideally at 9 months concomitantly with measles vaccine 4, 2
Age ≥2 years: Either conjugate vaccine (single dose) or parenteral inactivated vaccine (two doses)
Age ≥6 years: Oral Ty21a becomes more practical (four-capsule series)
Booster Considerations
- Parenteral inactivated vaccine: Booster every 3 years if continued exposure 1
- Conjugate vaccines: Data suggest booster at 15 months if initial dose given at 9 months, with longer intervals (6+ months) between doses showing better response than shorter intervals 6
Critical Clinical Pitfalls
Avoid these common errors:
- Don't use oral Ty21a in immunocompromised children or those with HIV 1
- Don't give oral vaccine to children who cannot reliably swallow capsules whole
- Don't assume typhoid vaccine alone provides complete protection—counsel families that vaccine efficacy is 85% at best and food/water precautions remain essential 2
- Don't delay vaccination in endemic settings waiting for "optimal" age—even 6-month-olds benefit from parenteral vaccine when risk is high
The evidence strongly favors conjugate vaccines at 9 months of age as the optimal approach, combining with routine measles vaccination for programmatic efficiency 4, 2.